MedTrace Logo

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

NCT04679545 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-02-02

No results posted yet for this study

Summary

The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

CBD

A water-soluble sublingual tablet containing 20 mg of CBD.

DRUG

Placebo

An inactive compound.

Sponsors & Collaborators

  • Pure Green

    lead INDUSTRY

Principal Investigators

  • Debra Kimless, M.D. · Pure Green Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2021-03-01
Completion
2021-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679545 on ClinicalTrials.gov